×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Lung Cancer

Katie Kosko
A new study showed that a large percentage of patients do not receive standard-of-care.
Kristie L. Kahl
As the Philadelphia Eagles and New England Patriots fight for claim over the Super Bowl trophy tonight, two lung cancer survivor advocates are in Minneapolis fighting for another reason: to raise research and awareness dollars.
Lysa Buonanno
When I learned that lung cancer is the number one cancer killer in the United States, but one of the lowest funded for research, it made me angry.
Brielle Urciuoli
Not all patients with non-small cell lung cancer (NSCLC) respond to immunotherapy, so researchers are exploring the use of combination regimens, including immune checkpoint inhibitors and chemotherapy, to improve outcomes in these patients. 
 
Helen C
Remembering her lasting legacy. 
Kristie L. Kahl
Clinical trials designed to evaluate the use of anti-cancer drugs for the treatment of cancer typically exclude patients whose disease has spread to the brain or CNS for a number of reasons, including the misperception that they are poor clinical trial candidates.
Marina Chiara Garassino, M.D.
Marina Chiara Garassino, M.D., talks about how immunotherapy agents have vastly improved the treatment field of patients with non-small cell lung cancer.
Silas Inman
The Food and Drug Administration (FDA) expanded the approved use for Gilotrif (afatinib). The drug can now be used to treat patients with metastatic non-small cell lung cancer (NSCLC) who have uncommon EGFR alterations in L861Q, G719X and/or S768I.
Brielle Urciuoli
Racial and socioeconomic status disparities can affect all types of lung cancer treatment – including surgery, chemotherapy and radiation. However, researchers may not be aware of this, since many of these groups are underrepresented in lung cancer clinical trials.
Brielle Urciuoli
“As the population of cancer survivors continues to grow, so does the importance of addressing the long-term sequelae of cancer treatment,” the authors wrote. “This hearing loss can result in multifaceted decrease in quality of life, and in pediatric patients it can impact social and academic development.”
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable